GSK (GSK) and Pfizer's (PFE) respiratory syncytial virus vaccines will carry warnings of increased risk of Guillain-Barre Syndrome, the US Food and Drug Administration said Tuesday on its website.
Results from a post-marketing observational study suggested an increased risk of Guillain-Barre Syndrome (GBS) during the 42 days after vaccination with Pfizer's Abrysvo and GSK's Arexvy, the FDA said.
GBS is a rare disorder in which the body's immune system damages nerve cells, causing muscle weakness and sometimes paralysis.
The FDA said it has "determined that the overall body of evidence suggests increased risks of GBS with Abrysvo and Arexvy, but that available evidence is insufficient to establish a causal relationship."
"FDA has required and approved safety labeling changes to the Prescribing Information for Abrysvo and Arexvy," the regulator said.
"FDA has further determined that the benefits of vaccination with Abrysvo and Arexvy continue to outweigh their risks," it added.
GSK and Pfizer didn't immediately respond to requests for comment by MT Newswires.
Price: 33.62, Change: -0.48, Percent Change: -1.39
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。